SCHEMBL5651069

SCHEMBL5651069

O=C(NCCCN1CCOCC1)c1ccc(-c2nc3ccc(C(F)(F)F)cc3[nH]2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HSD17B10 Q99714 3/20 0.48
HPGD P15428 2/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
GAA P10253 2/20 0.45
GLA P06280 1/20 0.45
CD274 Q9NZQ7 1/20 0.44
FLT3 P36888 1/20 0.44
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
DGAT1 O75907 1/20 0.43
SOAT1 P35610 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651073 0.93 MEN1 (0.51) MEN1KMT2AL3MBTL1KDM4EALDH1A1
SCHEMBL5653799 0.85 CD274 (0.59) KDM4EALDH1A1POLBSMN1; SMN2CD274
SCHEMBL5651258 0.84 L3MBTL1 (0.51) MEN1KMT2AL3MBTL1KDM4EALDH1A1
SCHEMBL5651264 0.84 L3MBTL1 (0.51) MEN1KMT2AL3MBTL1KDM4EALDH1A1
SCHEMBL5652813 0.82 L3MBTL1 (0.51) MEN1KMT2AL3MBTL1KDM4EALDH1A1
SCHEMBL5652805 0.82 MEN1 (0.51) MEN1KMT2AL3MBTL1KDM4EALDH1A1
SCHEMBL5650213 0.81 FLT3 (0.53) KDM4EALDH1A1POLBSMN1; SMN2CYP2D6
SCHEMBL5648124 0.81 TSHR (0.52) KDM4EALDH1A1POLBSMN1; SMN2CYP2D6
SCHEMBL5649698 0.81 FLT3 (0.50) POLBSMN1; SMN2CYP2D6CD274FLT3
SCHEMBL5648366 0.80 ACKR3 (0.47) MEN1KMT2AKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 MEN1 3545/4885KMT2A 439/4885L3MBTL1 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.